Parkwood LLC Acquires 7,225 Shares of CVS Health Co. (NYSE:CVS)

Parkwood LLC grew its holdings in shares of CVS Health Co. (NYSE:CVS) by 3.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 199,277 shares of the pharmacy operator’s stock after acquiring an additional 7,225 shares during the period. Parkwood LLC’s holdings in CVS Health were worth $8,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Coppell Advisory Solutions LLC grew its position in CVS Health by 17.3% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator’s stock worth $56,000 after buying an additional 189 shares during the period. EagleClaw Capital Managment LLC raised its position in shares of CVS Health by 3.4% in the fourth quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator’s stock valued at $275,000 after buying an additional 200 shares during the last quarter. Manchester Capital Management LLC boosted its holdings in shares of CVS Health by 4.8% during the fourth quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator’s stock worth $200,000 after purchasing an additional 204 shares during the last quarter. Angeles Investment Advisors LLC increased its stake in CVS Health by 3.7% in the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator’s stock valued at $256,000 after purchasing an additional 204 shares during the last quarter. Finally, Rogco LP lifted its position in CVS Health by 3.2% during the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator’s stock worth $303,000 after buying an additional 210 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Down 6.7%

NYSE CVS opened at $60.50 on Wednesday. The stock has a market cap of $76.53 billion, a PE ratio of 16.53, a P/E/G ratio of 0.98 and a beta of 0.60. The business has a 50 day moving average price of $66.84 and a two-hundred day moving average price of $59.15. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. During the same period last year, the business earned $1.31 EPS. The business’s revenue was up 7.0% on a year-over-year basis. As a group, sell-side analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.40%. CVS Health’s dividend payout ratio (DPR) is 63.48%.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $80.00 to $81.00 and gave the company an “overweight” rating in a research note on Tuesday, February 18th. Robert W. Baird increased their price target on shares of CVS Health from $51.00 to $71.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 15th. Barclays boosted their price objective on shares of CVS Health from $73.00 to $82.00 and gave the company an “overweight” rating in a research note on Friday, May 2nd. Morgan Stanley reiterated an “overweight” rating on shares of CVS Health in a report on Tuesday, April 15th. Finally, Evercore ISI upped their price target on CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research note on Monday, January 27th. Three analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $74.94.

Insider Transactions at CVS Health

In other CVS Health news, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP James David Clark sold 7,513 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. This represents a 47.23% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.